1
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective. Oncologist. 15(Suppl
4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Lau WY, Lai EC and Lau SH: The current
role of neoadjuvant/adjuvant/chemoprevention therapy in partial
hepatectomy for hepatocellular carcinoma: a systematic review.
Hepatobiliary Pancreat Dis Int. 8:124–133. 2009.PubMed/NCBI
|
4
|
Menon KV, Hakeem AR and Heaton ND: Review
article: liver transplantation for hepatocellular carcinoma - a
critical appraisal of the current worldwide listing criteria.
Aliment Pharmacol Ther. 40:893–902. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bryant R, Laurent A, Tayar C, van Nhieu
JT, Luciani A and Cherqui D: Liver resection for hepatocellular
carcinoma. Surg Oncol Clin N Am. 17:607–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lencioni R: Loco-regional treatment of
hepatocellular carcinoma. Hepatology. 52:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lau WY and Lai EC: The current role of
radiofrequency ablation in the management of hepatocellular
carcinoma: a systematic review. Ann Surg. 249:20–25. 2009.
View Article : Google Scholar
|
8
|
Obara K, Matsumoto N, Okamoto M, et al:
Insufficient radiofrequency ablation therapy may induce further
malignant transformation of hepatocellular carcinoma. Hepatol Int.
2:116–123. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kong J, Kong J, Pan B, et al: Insufficient
radiofrequency ablation promotes angiogenesis of residual
hepatocellular carcinoma via HIF-1α/VEGFA. PloS One. 7:e372662012.
View Article : Google Scholar
|
10
|
Zhao K, Song X, Huang Y, et al: Wogonin
inhibits LPS-induced tumor angiogenesis via suppressing
PI3K/Akt/NF-κB signaling. Eur J Pharmacol. 737:57–69. 2014.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kaseb AO, Morris JS, Hassan MM, et al:
Clinical and prognostic implications of plasma insulin-like growth
factor-1 and vascular endothelial growth factor in patients with
hepatocellular carcinoma. J Clin Oncol. 29:3892–3899. 2011.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Dong S, Kong J, Kong F, et al:
Insufficient radiofrequency ablation promotes
epithelial-mesenchymal transition of hepatocellular carcinoma cells
through Akt and ERK signaling pathways. J Transl Med. 11:2732013.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
15
|
Yamada S, Utsunomiya T, Morine Y, et al:
Expressions of hypoxia-inducible factor-1 and epithelial cell
adhesion molecule are linked with aggressive local recurrence of
hepatocellular carcinoma after radiofrequency ablation therapy. Ann
Surg Oncol. 21(Suppl 3): S436–S442. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Santoni M, Berardi R, Amantini C, et al:
Role of natural and adaptive immunity in renal cell carcinoma
response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer.
134:2772–2777. 2014. View Article : Google Scholar
|
17
|
Xue L, Li M, Chen T, et al: PE-induced
apoptosis in SMMC-7721 cells: Involvement of Erk and Stat
signalling pathways. Int J Mol Med. 34:119–129. 2014.PubMed/NCBI
|
18
|
Maier LS: Role of CaMKII for signaling and
regulation in the heart. Front Biosci (Landmark Ed). 14:486–496.
2009. View Article : Google Scholar
|
19
|
Russo E, Salzano M, De Falco V, et al:
Calcium/Calmodulin-dependent protein kinase II and its endogenous
inhibitor alpha in medullary thyroid cancer. Clin Cancer Res.
20:1513–1520. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Rusciano MR, Salzano M, Monaco S, et al:
The Ca2+-calmodulin-dependent kinase II is activated in papillary
thyroid carcinoma (PTC) and mediates cell proliferation stimulated
by RET/PTC. Endocr Relat Cancer. 17:113–123. 2010. View Article : Google Scholar
|